Endpoints News

Replimune names commercial chief as launch looms		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Th Fri

21 August, 2026

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

news

Exclusive: Two GOP lawmakers call on FDA to increase scrutiny of Chinese trial data following deaths

•

In Focus

Three deaths in China shake trust in the country's speedy clinical trial system

Peer Review

Replimune lands commercial chief after hard-fought approval; Neumora's Paul Berns sheds CEO title

Exclusive: PhRMA considers a grab-bag of Republican policy wonks, former lawmakers for CEO post

Aug 27

12:00 pm ET

Same molecule, different paths: Where value goes in cross-border dealmaking in a new era

in case you missed it

FDA rejects Osteal combo therapy to treat joint-implant infections

Using gray-market versions of Lilly’s triple-G leads to relatively poor weight loss, study finds

Ultragenyx's gene therapy gets FDA OK for glycogen storage disorder

News Briefing

Lilly partners with Amplitude on vaccines; Otsuka scraps psychedelic trial

Europe has its own biotech star as Argenx soars on trial success

U.S. workers are paying more for healthcare, and next year will be worse

The fallout from the patient deaths in investigator-led trials in China continues. Endpoints' Max Bayer reports today that two US politicians are calling for a clampdown on clinical data from China, and for the FDA to assess approved drugs’ use of Chinese results.

Elizabeth Cairns

Senior Biopharma Journalist, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com

Endpoints Studio
Endpoints Webinars

Endpoints Events
Biopharma Jobs

Worldwide made. Thanks for reading.